- Accueil
- Récupération et régénération
- Cartalax, 20mg
Cartalax, 20mg
Cartalax is a cartilage-derived short peptide bioregulator from the Khavinson series with proposed tissue-specific regulatory activity in cartilaginous tissue.
Conditionnement: Cartalax, 20mg.
Conditionnement illustratif généré par IA.
- Pharmacie partenaire
- Accompagnement personnalisé
- Livraison discrète
- ConditionnementCartalax, 20mg
Expédition et livraison
- Expédition habituellement sous 24 heures après confirmation du paiement.
- USPS Regular Shipping · 11,95 € · Env. 3–5 jours ouvrés
- FedEx 2 Days Delivery · 28,99 € · Env. 2 jours ouvrés
- FedEx Overnight Delivery · 40,99 € · Env. 1 jour ouvré
Réservé à la recherche en laboratoire.
Ne pas utiliser chez l’être humain ou l’animal.
Composition et détails du produit
Présentation
Cartalax is a cartilage-derived short peptide bioregulator from the Khavinson series with proposed tissue-specific regulatory activity in cartilaginous tissue. Research from the originating laboratory reports effects on chondrocyte signalling, collagen II synthesis, proteoglycan expression, and extracellular matrix regulation.
Research applications include cartilage biology, chondrocyte function, ECM pathway investigation, and short peptide bioregulator mechanism studies. Independently third-party HPLC-tested; COA available per batch.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
Propriétés
| Chemical Formula | C12H19N3O8 |
|---|---|
| Synonyms | T-31, AED, SCHEMBL5324601, Alanyl-glutamyl-aspartic acid |
| Molar Mass | 333.29 g/mol |
| CAS Number | 205640-90-0 |
| PubChem CID | 87815447 |
| Total Compound Content | 20 mg per vial |
| Shelf Life | 36 months |
Recherche
Cartalax is a cartilage-derived short peptide bioregulator from the Khavinson series with proposed tissue-specific regulatory activity in cartilaginous tissue. Research from the originating laboratory reports effects on chondrocyte signalling, collagen II synthesis, proteoglycan expression, and extracellular matrix regulation. Research applications include cartilage biology, chondrocyte function, ECM pathway investigation, and short peptide bioregulator mechanism studies. Independently third-party HPLC-tested; COA available per batch.
FAQ
What cartilage extracellular matrix markers have been examined in Cartalax research?
Research from the originating laboratory has focused on key cartilage extracellular matrix markers including collagen type II, aggrecan, and SOX9, which are central regulators of chondrocyte phenotype and cartilage matrix production. These markers are commonly used to evaluate cartilage signalling, extracellular matrix maintenance, and chondrocyte activity in experimental models.
How does Cartalax fit within the Khavinson bioregulator series?
Cartalax is the cartilage-focused member of the Khavinson peptide bioregulator series. Similar to other organ-specific bioregulators, it is proposed to influence tissue-specific regulatory pathways and is primarily investigated in studies involving cartilage biology, chondrocyte function, extracellular matrix regulation, and peptide-mediated gene expression mechanisms.
What experimental models are commonly used to investigate Cartalax?
Common models include primary chondrocyte cultures, cartilage-derived cell lines, three-dimensional cartilage culture systems, and rodent cartilage research models. Frequently measured endpoints include collagen II expression, aggrecan production, SOX9 signalling, extracellular matrix composition, glycosaminoglycan content, and chondrocyte proliferation markers.